Xenograft studies for the Marine Fungi Consortium

European ScreeningPort GmbH

A group of eleven institutions from seven different countries has jointly set up a consortium of experts to cooperatively conduct the project 'MARINE FUNGI', which received funding from the European Commission under the 'Seventh Framework Programme' (FP7). The project is coordinated by the 'Helmholtz Zentrum für Ozeanforschung (GEOMAR)' Kiel, Germany.
The aim of MARINE FUNGI is to demonstrate the sustainable exploitation of under-utilised marine natural resources, namely fungi isolated from various marine sources. As well as demonstrating the efficient and scalable production of marine natural products, the project has been exploring marine fungi as a source of useful new natural compounds, with a therapeutic focus on the development of novel anti-cancer compounds. The scope of the project includes the characterization of the most promising compounds to the stage of in vivo proof of concept of anti-tumour efficacy.
Compounds with desirable characteristics and confirmed dose dependent in vitro biological activity in the context of the NCI60 collection of cancer cell lines1, will be subject to increasingly detailed assessment in higher content/value assays. The best compounds will be selected on the basis of in vitro compound efficacy performance, appropriate pharmaceutical potential and in vivo pharmacokinetic (PK) profiles. Following in vivo PK studies and maximum tolerable dose assessment, up to 5 promising compounds will be analysed in Xenograft mouse models.
The objective is to define and document the requirements for the determination of the anti-tumour efficacy of selected compounds in Xenograft mouse model studies of up to 5 compounds for the MARINE FUNGI Consortium.

Deadline

Die Frist für den Eingang der Angebote war 2013-12-06. Die Ausschreibung wurde veröffentlicht am 2013-11-27.

Wer? Wie? Wo?
Geschichte der Beschaffung
Datum Dokument
2013-11-27 Auftragsbekanntmachung
Auftragsbekanntmachung (2013-11-27)
Objekt
Umfang der Beschaffung
Titel: Dienstleistungen im Bereich Forschung und experimentelle Entwicklung
Menge oder Umfang:
Xenograft mouse model studies of up to 5 compounds for the MARINE FUNGI Consortium.5 00070 000
Metadaten der Bekanntmachung
Originalsprache: Englisch 🗣️
Dokumenttyp: Auftragsbekanntmachung
Art des Auftrags: Dienstleistungen
Verordnung: Europäische Union
Gemeinsames Vokabular für öffentliche Aufträge (CPV)
Code: Dienstleistungen im Bereich Forschung und experimentelle Entwicklung 📦

Verfahren
Verfahrensart: Offenes Verfahren
Angebotsart: Angebot für alle Lose
Vergabekriterien
Wirtschaftlichstes Angebot

Öffentlicher Auftraggeber
Identität
Land: Deutschland 🇩🇪
Art des öffentlichen Auftraggebers: Sonstiges
Name des öffentlichen Auftraggebers: European ScreeningPort GmbH
Postanschrift: Schnackenburgallee 114
Postleitzahl: 22525
Postort: Hamburg
Kontakt
Internetadresse: http://www.screeningport.com 🌏
E-Mail: tender@screeningport.com 📧
Telefon: +49 403037640 📞
Fax: +49 40303764100 📠

Referenz
Daten
Absendedatum: 2013-11-27 📅
Einreichungsfrist: 2013-12-06 📅
Veröffentlichungsdatum: 2013-11-29 📅
Kennungen
Bekanntmachungsnummer: 2013/S 232-402869
ABl. S-Ausgabe: 232

Objekt
Umfang der Beschaffung
Geschätzter Wert ohne MwSt: 5 000 💰
70 000 💰
Häufigkeit der zu vergebenden Aufträge: 2
Kurze Beschreibung:
A group of eleven institutions from seven different countries has jointly set up a consortium of experts to cooperatively conduct the project 'MARINE FUNGI', which received funding from the European Commission under the 'Seventh Framework Programme' (FP7). The project is coordinated by the 'Helmholtz Zentrum für Ozeanforschung (GEOMAR)' Kiel, Germany.
Mehr anzeigen
The aim of MARINE FUNGI is to demonstrate the sustainable exploitation of under-utilised marine natural resources, namely fungi isolated from various marine sources. As well as demonstrating the efficient and scalable production of marine natural products, the project has been exploring marine fungi as a source of useful new natural compounds, with a therapeutic focus on the development of novel anti-cancer compounds. The scope of the project includes the characterization of the most promising compounds to the stage of in vivo proof of concept of anti-tumour efficacy.
Mehr anzeigen
Compounds with desirable characteristics and confirmed dose dependent in vitro biological activity in the context of the NCI60 collection of cancer cell lines1, will be subject to increasingly detailed assessment in higher content/value assays. The best compounds will be selected on the basis of in vitro compound efficacy performance, appropriate pharmaceutical potential and in vivo pharmacokinetic (PK) profiles. Following in vivo PK studies and maximum tolerable dose assessment, up to 5 promising compounds will be analysed in Xenograft mouse models.
Mehr anzeigen
The objective is to define and document the requirements for the determination of the anti-tumour efficacy of selected compounds in Xenograft mouse model studies of up to 5 compounds for the MARINE FUNGI Consortium.
Losnummer: 1
Bezeichnung des Loses: Xenograft studies for the Marine Fungi Consortium - compound 1
Zusätzliche Angaben zu den Losen:
The orders for each of the 5 Xenograft mouse studies (Lots) will be placed individually by a specific partner of the MARINE FUNGI consortium on behalf of the consortium and as well invoiced individually to the respective partner.
Losnummer: 2
Bezeichnung des Loses: Xenograft studies for the Marine Fungi Consortium - compound 2
Losnummer: 3
Bezeichnung des Loses: Xenograft studies for the Marine Fungi Consortium - compound 3
Losnummer: 4
Bezeichnung des Loses: Xenograft studies for the Marine Fungi Consortium - compound 4
Losnummer: 5
Bezeichnung des Loses: Xenograft studies for the Marine Fungi Consortium - compound 5
Es werden Varianten akzeptiert ✅
Menge oder Umfang:
Xenograft mouse model studies of up to 5 compounds for the MARINE FUNGI Consortium.
Bezeichnung des von der EU finanzierten Projekts oder Programms:
Marine fungi
THEME [KBBE.2010.3.2-01] [Sustainable culture of marine microorganisms, algae and/or invertebrates for high added value products - Call: FP7-KBBE-2010-4]

Rechtliche, wirtschaftliche, finanzielle und technische Informationen
Bedingungen für die Teilnahme
Mindeststandards:
We are obliged to assure the humane care and use of the animals in the care of the provider of the in vivo studies commissioned by the MARINE FUNGI consortium. With these studies we are aiming at accelerating and enhancing our drug research and development efforts in order to advance new therapies faster and more cost efficiently.
Mehr anzeigen
It is presupposed that provider is committed to compliance with both the letter and spirit of the laws and regulations relating to the care and use of research animals and with all applicable policies and operating procedures.
Auftragsausführung
Geforderte Kautionen und Garantien: no
Sonstige besondere Bedingungen:
The consortium is expecting a combined quote for all 5 Xenograft mouse studies on behalf of the MARINE FUNGI consortium. It should be directed to the following address:
Dr. Philip Gribbon
European ScreeningPort GmbH
Schnackenburgallee 114
22525 Hamburg
GERMANY
The orders for each of the 5 Xenograft mouse studies will be placed individually by a specific partner of the MARINE FUNGI consortium on behalf of the consortium and as well invoiced individually to the respective partner. The Xenograft mouse studies will be ordered in packages of 2 followed by 3 studies. The MARINE FUNGI consortium would prefer to place the orders for the Xenograft mouse studies with the same provider as the additionally planned MTD studies. Please review the URS 'MTD studies for MARINE FUNGI' (separate document).
Mehr anzeigen
The first closing date for receipt of applications will be 6.12.2013.
The intellectual property that may be generated in the course of this study, fully reverts to the MARINE FUNGI consortium.

Verfahren
Laufzeit der Rahmenvereinbarung in Monaten: 3
Sprachen
Sprache: Englisch 🗣️

Öffentlicher Auftraggeber
Identität
Andere Art des öffentlichen Auftraggebers: Other
Name des öffentlichen Auftraggebers: Marine Fungi Consortium at GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel
Postanschrift: Wischhofstr. 1-3
Postort: Kiel
Postleitzahl: 24148
Kontakt
Kontaktperson: European ScreeningPort GmbH - Marine fungi
Dr. Mira Grättinger
Internetadresse: www.screeningport.com 🌏
Adresse des Käuferprofils: http://www.marinefungi.eu 🌏

Referenz
Daten
Datum des Beginns: 2013-12-08 📅
Datum des Endes: 2014-03-07 📅
Quelle: OJS 2013/S 232-402869 (2013-11-27)
Neue Beschaffungen in verwandten Kategorien 🆕
Verwandte Suchen 🔍
Produkte/Dienstleistungen:
Forschungs- und Entwicklungsdienste und... Dienstleistungen im Bereich Forschung und... Forschungsdienste Experimentelle Entwicklung Planung und Ausführung von Forschung und...